Daniel L. Simmons

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Daniel L. Simmons is a professor of chemistry and the director of the Cancer Research Center at Brigham Young University (BYU). He was the discoverer of the COX-2 enzyme that is the target of celecoxib (Celebrex) and other COX-2 inhibitors. He and BYU felt that Pfizer had not properly credited or paid them for Simmons work in this development and brought a suit against Pfizer.

Simmons has bachelors and masters degrees from BYU. He earned his Ph.D. from the University of Wisconsin in 1986. From 1986-1989 he held a post-doctoral Fellowship at Harvard University.

Simmons discovered the COX-2[1] and COX-3 enzymes.

References[edit]

  1. ^ Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (April 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America 88 (7): 2692–6. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272. 

Sources[edit]